Short answer
Gilead Sciences (GILD) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $7.0B (up 4.4% year over year) with net income of $2.0B.
Q1 2026 key financials · XBRL
- Revenue
- $7.0B
- +4.4% YoY
- Net income
- $2.0B
- +53.7% YoY
- Operating margin
- 37.2%
- EPS (diluted)
- $1.61
- +54.8% YoY
Source: XBRL data from the Gilead Sciences (GILD) Q1 2026 10-Q on SEC EDGAR. USD.
Gilead Sciences Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $6.96B, up 4% YoY from $6.667B
- Product gross margin 79.2% vs 76.7% YoY
- Best line: HIV revenue $5.03B, up 10%; Descovy up 38% to $807M
- Worst line: Veklury revenue $144M, down 52%; Cell Therapy $407M, down 12%
- Q2 and full-year 2026 net loss expected from approximately $11.5B acquisition-related IPR&D charges
Risk Factors
- Newly triggered tariff risk: April 2026 Proclamation imposing 100% tariffs on patented pharmaceuticals and ingredients, potentially increasing costs and disrupting supply chains
- Most materially updated pricing risk: HHS selected Biktarvy for Maximum Fair Price determination effective 2028, potentially reducing Medicare, Medicaid, and 340B pricing
- Compliance risk: 340B contract-pharmacy integrity initiative faces HHS enforcement, state laws, and ongoing litigation across federal circuits
- Near-term demand risk: Florida ADAP removed Biktarvy from its formulary and restricted Descovy access in March 2026
- Distribution concentration risk: Approximately 90% of U.S. gross product sales historically flowed through three wholesalers
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gilead Sciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.